Literature DB >> 31143671

Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats.

Yvonne Konkol1,2, Heikki Vuorikoski2, Tomi Streng3,4, Johanna Tuomela1, Jenni Bernoulli2.   

Abstract

BACKGROUND: Chronic nonbacterial prostatitis associated with lower urinary tract symptoms (LUTS) is a prevalent condition in men. One potential pathophysiological factor is change in sex hormone, testosterone and estrogen, balance. Inflammation, cancer and obstructive voiding has been induced in the Noble rat strain by altering levels of sex hormones. We evaluated if imbalance of sex hormones could induce comparable diseases also in a less estrogen sensitive Wistar strain rats.
METHODS: Subcutaneous testosterone (830 µg/day) and 17β-estradiol (83 µg/day) hormone pellets were used in male Wistar and Noble strain rats to induce prostatic diseases. The rats were followed for 13 and 18 weeks. Urodynamical measurements were performed at the end of the study under anesthesia. Prostates were collected for further histological analysis. A panel of cytokines were measured from collected serum samples.
RESULTS: Noble rats exhibited stromal and glandular inflammation after 13 weeks that progressed into more severe forms after 18 weeks of hormonal treatment. CD68-positive macrophages were observed in the stromal areas and inside the inflamed acini. CD163-positive macrophages were present in the stromal compartment but absent inside inflammatory foci or prostate acini. Thirteen-week hormonal treatment in Noble rats induced obstructive voiding, which progressed to urinary retention after 18-weeks treatment. In the Wistar rats 18-week treatment was comparable to the 13-week-treated Noble rats judged by progression of prostatic inflammation, being also evident for obstructive voiding. Incidence of PIN-like lesions and carcinomas in the periurethal area in Noble rats were high (100%) but lower (57%) and with smaller lesions in Wistar rats. Serum cytokines leptin, CCL5, and VEGF concentrations showed a decrease in the hormone-treated rats compared to placebo-treated rats.
CONCLUSIONS: Prostate inflammation and obstructive voiding developed also in the Wistar rats but more slowly than in Noble rats. Male non-castrated Wistar strain rats may thus be suitable to use in studies of pathophysiology and hormone-dependent prostate inflammation and obstructive voiding.

Entities:  

Keywords:  Disease model; estrogens; lower urinary tract symptoms (LUTS); prostatitis; testosterone

Year:  2019        PMID: 31143671      PMCID: PMC6511689          DOI: 10.21037/tau.2019.02.03

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


  44 in total

1.  Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison.

Authors:  R M Levin; N Haugaard; L O'Connor; R Buttyan; A Das; J S Dixon; J A Gosling
Journal:  Neurourol Urodyn       Date:  2000       Impact factor: 2.696

2.  A detailed study on the role of sex steroid milieu in determining plasma leptin concentrations in adult male and female rats.

Authors:  H Watanobe; T Suda
Journal:  Biochem Biophys Res Commun       Date:  1999-05-27       Impact factor: 3.575

Review 3.  Urinary bladder contraction and relaxation: physiology and pathophysiology.

Authors:  Karl-Erik Andersson; Anders Arner
Journal:  Physiol Rev       Date:  2004-07       Impact factor: 37.312

Review 4.  Prostatitis/chronic pelvic pain syndrome.

Authors:  Geoffrey M Habermacher; Judd T Chason; Anthony J Schaeffer
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

5.  A dose-dependent dual effect of oestrogen on voiding in the male mouse?

Authors:  Tomi K Streng; Antti Talo; Karl-Erik Andersson; Risto Santti
Journal:  BJU Int       Date:  2005-11       Impact factor: 5.588

6.  Possible action of the proximal rhabdosphincter muscle in micturition of the adult male rat.

Authors:  T Streng; R Santti; A Talo
Journal:  Neurourol Urodyn       Date:  2001       Impact factor: 2.696

7.  Infravesical obstruction in aromatase over expressing transgenic male mice with increased ratio of serum estrogen-to-androgen concentration.

Authors:  Tomi Streng; Xiangdong Li; Mari Lehtoranta; Sari Mäkelä; Matti Poutanen; Antti Talo; Rajeshwar Rao Tekmal; Risto Santti
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

8.  Intraprostatic lymphocyte profiles in aged wistar rats with estradiol induced prostate inflammation.

Authors:  Eugene V Vykhovanets; Martin I Resnick; Susan Ruth Marengo
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

9.  Serum sex hormones and measures of benign prostatic hyperplasia.

Authors:  Rosebud O Roberts; Debra J Jacobson; Thomas Rhodes; George G Klee; Michael M Leiber; Steven J Jacobsen
Journal:  Prostate       Date:  2004-10-01       Impact factor: 4.104

10.  Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat.

Authors:  Michael J Wilson; Mildred Woodson; Carol Wiehr; Avinash Reddy; Akhouri A Sinha
Journal:  Exp Mol Pathol       Date:  2004-08       Impact factor: 3.362

View more
  3 in total

Review 1.  Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases.

Authors:  Joosje Bleeker; Zhu A Wang
Journal:  Front Mol Biosci       Date:  2022-07-05

2.  Genetic background but not prostatic epithelial beta-catenin influences susceptibility of male mice to testosterone and estradiol-induced urinary dysfunction.

Authors:  Kyle A Wegner; Hannah Ruetten; Nicholas M Girardi; Chelsea A O'Driscoll; Jaskiran K Sandhu; Anne E Turco; Lisa L Abler; Peiqing Wang; Zunyi Wang; Dale E Bjorling; Rita Malinowski; Richard E Peterson; Douglas W Strand; Paul C Marker; Chad M Vezina
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

Review 3.  Male Lower Urinary Tract Dysfunction: An Underrepresented Endpoint in Toxicology Research.

Authors:  Nelson T Peterson; Chad M Vezina
Journal:  Toxics       Date:  2022-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.